Genetic Technologies (ASX:GTG) has introduced geneType’s suite of genetic risk assessment tests to Canada and New Zealand.
The introduction in these markets follows the recent expansion to the US market under a partnership with health and wellness technology company Stayhealthy.
Stayhealthy Canada and Stayhealthy New Zealand will direct the distribution of the geneType risk assessment test in the new territories.
“We are anticipating accelerated growth as we enter Canada and New Zealand,” said geneType CEO Simon Morriss.
“Coupled with our expansion into new territories, our full-scale marketing efforts have successfully increased consumer awareness and trust that is translating into unprecedented growth.”
The first geneType assessment for breast cancer was developed in 2022 after 20 years of research stemming from Genetic Technologies contributions to the Human Genome Project. The company has since developed a comprehensive suite of innovative tests evaluating genetic and traditional risks for various diseases.
